Biogen Inc. (BIIB)
Chart Events
Performance Outlook
| Previous Close | 269.94 |
| Open | 269.88 |
| Bid | 271.38 x 900 |
| Ask | 271.55 x 800 |
| Day's Range | 267.02 - 272.61 |
| 52 Week Range | 223.25 - 468.55 |
| Volume | 667,099 |
| Avg. Volume | 983,798 |
| Market Cap | 40.765B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 14.04 |
| EPS (TTM) | 19.29 |
| Earnings Date | Oct 19, 2021 - Oct 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 417.70 |
- Barrons.com
Eli Lilly Is Asking the FDA to Approve Its Alzheimer’s Therapy
The drugmaker has started the process of submitting its Alzheimer’s disease therapy donanemab for approval.
- MarketWatch
Lilly plans to run clinical trial comparing its Alzheimer's drug candidate to Biogen's Aduhelm
Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administration for its experimental Alzheimer's drug, donanemab. It also said it plans to conduct a Phase 3 clinical trial evaluating donanemab against Aduhelm, Biogen Inc.'s recently approved Alzheimer's drug, to assess "superiority of brain amyloid plaque clearance in early symptomati
- Motley Fool
3 Big Problems With Biogen's Q3 Results
Biogen (NASDAQ: BIIB) announced its third-quarter results on Wednesday. It's certainly true that Biogen did top analysts' estimates on both the top and bottom lines. Instead, there were three big problems with Biogen's Q3 results.
